EGFR and neoplasm: In this study, we show that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor is effective against tumor cell lines refractory to gefitinib by three different mechanisms: an EGFR gatekeeper T790M mutation, MET amplification, and KRAS/PIK3CA mutation.